Dai­ichi Sankyo in­vests $1B to bulk out Ger­man site for can­cer AD­Cs 

Dai­ichi Sankyo is pour­ing €1 bil­lion ($1.07 bil­lion) in­to a Ger­man fa­cil­i­ty in part to ex­pand its ca­pac­i­ty for an­ti­body-drug con­ju­gate man­u­fac­tur­ing. The first part of the ex­pan­sion be­came op­er­a­tional last month, a com­pa­ny spokesper­son told End­points News.

The fa­cil­i­ty is in Pfaf­fen­hofen an der Ilm, which is a 40-minute dri­ve north of Mu­nich. The Japan­ese phar­ma will build a new lab for can­cer AD­Cs that will be fin­ished by 2026 in ad­di­tion to bol­ster­ing car­dio­vas­cu­lar dis­ease as­set pro­duc­tion. There is “in­creased glob­al de­mand for ADC can­cer ther­a­pies,” added Dai­ichi Eu­rope site man­ag­er Matthias Kühn in the press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER